Harvard
The machine learning framework extracts features from digital pathology slides to diagnose and predict multiple types of cancer.
Investigators published early case control data in a recent preprint showing remarkable sensitivity and are now considering their best options for further validation.
The Industrial Participant Program, part of the Wyss Diagnostics Accelerator, provides a hub for collaboration and guidance to move promising tech forward.
Sherlock Biosciences Licenses Ambient Temperature Amplification Tech From Wyss Institute
Sherlock plans to integrate the method with its CRISPR platform to develop instrument-free diagnostic assays for low-resource settings.
NanoMosaic Licenses Post-Operative Delirium Test From Mass General, Harvard Medical School
The test uses NanoMosiac's nanoneedle technology to diagnose patients with anesthesia-induced delirium and Alzheimer's disease.
Sep 2, 2022
Feb 17, 2021